DNDN--holding 95% of my original shares---not something to brag about, from as far back as 2001.
New CEO, new focus on lowering COG, expected greater usage by large urology groups as they get comfortable with reimbursement and administration of drug.
New 2-3 quarters are KEY to regain revenue growth and Wall Street's confidence. I am holding and buying under $11.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.